Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art.

导出 OA

翻译打印收藏纠错

作者： Gianluigi,Califano ^[1] ; Idir,Ouzaid ^[2] ; Paul,Laine-Caroff ^[2] ; Arthur,Peyrottes ^[2] ; Claudia,Collà Ruvolo ^[2] ; Benjamin,Pradère ^[1] ; Vincent,Elalouf ^[3] ; Vincent,Misrai ^[4] ; Jean-François,Hermieu ^[5] ; Shahrokh F,Shariat ^[2] ; Evanguelos,Xylinas ^[3]

作者单位： Urology Unit, Department of Neurosciences, Reproductive Sciences and Odontostomatology, Federico II University of Naples, 80131 Naples, Italy. ^[1] Department of Urology, Bichat-Claude Bernard Hospital, Assistance-Publique Hôpitaux de Paris, Paris University, 75018 Paris, France. ^[2] Department of Urology, Medical University of Vienna, 1090 Vienna, Austria. ^[3] Department of Urology, Hospital Claude Galien, 91480 Quincy-sous-Sénart, France. ^[4] Department of Urology, Clinique Pasteur, UMR-1048 Toulouse, France. ^[5] University of Paris, INSERM, Immunologie Humaine Physiopathologie & Immunothérapie, F-75010 Paris, France. ^[6]

关键词 genetics immune check point inhibition prognosis radical nephroureterectomy upper tract urothelial carcinoma

主题词癌, 移行细胞(Carcinoma, Transitional Cell);基因组学(Genomics);人类(Humans);肿瘤微环境(Tumor Microenvironment);膀胱肿瘤(Urinary Bladder Neoplasms)

DOI 10.3390/curroncol29020060

PMID 35200559

发布时间 2022-03-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交